Collegium Pharmaceutical, Inc. - Common Stock (COLL)
Competitors to Collegium Pharmaceutical, Inc. - Common Stock (COLL)
Egalet Corporation
Egalet Corporation specializes in the development of abuse-deterrent opioids and extended-release pain medications, positioning itself in direct competition with Collegium focused on similar technology for pain management. While they both emphasize safety and efficacy in their drug formulations, Collegium's market presence and established product approval provide it with a competitive advantage in terms of branding and market trust.
Hysingla ER (Zogenix, Inc.)
Zogenix, Inc. develops Hysingla ER, an extended-release opioid formulation for chronic pain management, directly competing with Collegium's Xtampza ER. While both companies operate in the same therapeutic area, Collegium's focus on abuse-deterrent technology gives it a strategic edge. Zogenix has had its challenges with post-marketing safety concerns that may hinder its competitiveness against Collegium, which has been proactive in marketing its safety-focused product.
Pain Therapeutics, Inc.
Pain Therapeutics, Inc. focuses on developing innovative therapies for chronic pain management, similar to Collegium Pharmaceutical's offerings. Both companies are engaged in creating and marketing pharmaceutical products that aim to address unmet medical needs in the pain management sector. Collegium, with its FDA-approved product Xtampza ER, provides strong competition by offering a unique abuse-deterrent formulation that appeals to both patients and healthcare providers, putting it at an advantage.
Purdue Pharma L.P.
Purdue Pharma has a long-standing presence in the opioid market, historically producing OxyContin. The competitive landscape shifted with the opioid crisis, prompting Purdue to explore reformulation and new therapies that facilitate pain management while reducing the risk of abuse. Collegium listens closely to market demands and capitalizes on developing abuse-deterrent formulations, establishing a competitive edge through innovation and evolving healthcare regulations surrounding opioids.